Top Spirometer Companies

Spirometer Market size was valued at USD 1.12 Billion in 2024 and is poised to grow from USD 1.22 Billion in 2025 to USD 2.34 Billion by 2033, growing at a CAGR of 8.52% during the forecast period (2026–2033).

The market is competitive and driven by technological factors and the expansion strategies implemented in the markets. Businesses are concerned with the improvement of spirometry tools to increase precision, ease of use, and patient tolerance. New entrants are gradually increasing their presence with niche products and partnerships. This category of strategies entails forming partnerships, mergers, and acquisitions to enhance market position and leverage the increasing demand for respiratory diagnostic solutions in the global market. 'MGC Diagnostics Corporation (US)', 'NDD Medical Technologies (Switzerland) ', 'Koninklijke Philips N.V. (Netherlands) ', 'Vitalograph Ltd. (UK) ', 'COSMED srl (Italy) ', 'Schiller AG (Switzerland) ', 'Midmark Corporation (US) ', 'Baxter International (Hill-Rom Services, Inc.) (US) ', 'Teleflex Incorporated (US) ', 'MIR (Medical International Research) (Italy) ', 'FUKUDA SANGYO CO., LTD. (Japan) ', 'Geratherm Medical AG (Germany) ', 'Vyaire Medical Inc. (US) ', 'Contec Medical Systems Co., Ltd. (China) ', 'Microlife Corporation (Taiwan) ', 'Jones Medical Instrument Company (US) ', 'Sibelmed (Spain) ', 'Nihon Kohden Corporation (Japan) ', 'ICU Medical, Inc. (US) ', 'KoKo PFT (US)'

The spirometers are demanding for early detection, disease management, and treatment intervention for people with respiratory disorders. In 2020, the COPD incidence was estimated 10.6% in both males and females, equivalent to 480 million cases. The estimates of COPD prevalence suggest that the figure of COPD patients will increase by 112 million by 2050, totaling 592 million or 9.3% from year 2020 to year 2050. This rising is mainly due to the increasing prevalence of COPD among female patients and LMICs. In females, COPD is expected to rise to 7.8% in 2020 to 8.3% in 2050. The number of the population aged 65 and over was 8% in 2020 and 8.3% in 2050, a relative increase of 6.4%. The global prevalence of COPD in females is projected to rise from 177 million in the year 2020 to 260 million by the year 2050, this a rise of 83 million, 47.1% relative increase.

Advancements in spirometry technology: The development of new spirometry devices is now experiencing fast-growing demand in the global market due to better usability, portability, and cheaper prices. Some of the advancements include portable devices that have greatly enhanced respiratory care through enhanced portability and convenience of the devices to both the carers and the patients. These portable equipments allow pulmonary function tests in non-hospital environments, particularly in point-of-care and telemedicine settings. For instance, in January 2024, the Air Next spirometer developed by NuvoAir is a breakthrough, as it is the first spirometer approved by the FDA for home use. Moreover, incorporation with Smartphones has emerged as a trend that utilizes the existing popular devices to improve usability. spirometers are integrated with smartphone applications, which track patients’ respiratory health and share the data with their healthcare providers for assessment and management without physically visiting the clinic.

North America held the largest market share in 2023 with 38.04% due to increasing incidences of respiratory diseases. Asthma and COPD incidence has led to higher spirometer sales because of disease necessity and acceptance among hospital doctors. Also, the United States has been at the forefront of embracing technologies to reduce the incidences of COPD. Such factors indicate that the market has good potential for growth in the future for the given forecast period. Chronic respiratory diseases are prevalent in the United States, which increases the need to monitor the conditions through portable handheld spirometers.